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Abstract
Purpose: Few patients with metastatic triple-negative breast cancer (mTNBC) benefit from 
immune checkpoint inhibitors (ICIs). Based on immunotherapy response correlates in other 
cancers, we evaluated whether high tumor mutational burden (TMB) ≥10 nonsynonymous 
mutations/megabase and PTEN alterations, defined as nonsynonymous mutations or 1 or 2 copy 
deletions, were associated with clinical benefit to anti-PD-1/ L1 therapy in mTNBC.
Experimental Design: We identified patients with mTNBC, who consented to targeted DNA 
sequencing and were treated with ICIs on clinical trials between April 2014 and January 2019 at 
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Dana-Farber Cancer Institute (Boston, MA). Objective response rate (ORR), progression-free 
survival (PFS), and overall survival (OS) were correlated with tumor genomic features.
Results: Sixty-two women received anti-PD-1/L1 inhibitors alone (23%) or combined with 
targeted therapy (19%) or chemotherapy (58%). High TMB (18%) was associated with 
significantly longer PFS (12.5 vs. 3.7 months; p=0.04); while PTEN alterations (29%) were 
associated with significantly lower ORR (6% vs. 48%; p=0.01), shorter PFS (2.3 vs. 6.1 months; 
p=0.01), and shorter OS (9.7 vs. 20.5 months; p=0.02). Multivariate analyses confirmed that these 
associations were independent of performance status, prior lines of therapy, therapy regimen, and 
visceral metastases. The survival associations were additionally independent of PD-L1 in patients 
with known PD-L1 and were not found in mTNBC cohorts treated with chemotherapy (n = 90) 
and non-ICI regimens (n = 169).
Conclusions: Among patients with mTNBC treated with anti-PD-1/L1 therapies, high TMB and 
PTEN alterations were associated with longer and shorter survival, respectively. These 
observations warrant validation in larger datasets.
Statement of Translational Relevance
This study investigates whether high tumor mutational burden (TMB) and PTEN alterations affect 
response to anti-PD-1/L1 therapies among patients with metastatic triple-negative breast cancer 
(mTNBC). High TMB and PTEN alterations correlate with clinical responses to immune 
checkpoint inhibitors in other tumors, but these associations have not been well studied in breast 
cancer. In this cohort of 62 women with mTNBC treated with anti-PD-1/L1 therapies, high TMB 
was associated with improved progression-free survival, while PTEN alterations were associated 
with reduced responses and progression-free and overall survival. These associations were 
independent of clinical confounders, as well as PD-L1 in patients with known PD-L1, and were 
not found in patients treated with non-immunotherapy regimens. Overall, high TMB and PTEN 
alterations were associated with better and worse outcomes, respectively, among patients with 
mTNBC treated with anti-PD-1/L1 therapies. These results warrant validation in larger prospective 
studies, including ongoing trials investigating whether AKT inhibitors reverse resistance to PD-1 
blockade.
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Introduction
Patients with metastatic triple-negative breast cancer (mTNBC) have limited treatment 
options and a poor prognosis with a median overall survival of 13 to 18 months.1 Despite the 
success of PD-1/L1 inhibitors in other cancers, their single-agent efficacy in mTNBC is low: 
monotherapy responses range from 5% in unselected cohorts to 25% in patients with PD-L1-
positive and/or treatment-naïve disease.2–5
Recently the IMpassion130 study showed that adding atezolizumab to nab-paclitaxel 
improved progression-free survival (PFS) and overall survival (OS) in patients with 
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treatment-naïve PD-L1-positive mTNBC.6 Based on these data, this combination was 
granted accelerated approval for the treatment of mTNBC with ≥ 1% PD-L1 expression on 
immune cells.6 However, there are still open questions surrounding the broad utility of PD-
L1 testing for selecting patients for immune checkpoint inhibitors (ICIs), and additional 
biomarkers to predict benefit are being investigated.
Given its close association with neoantigen burden and T-cell infiltration,7–10 tumor 
mutational burden (TMB) is one marker of tumor antigenicity.11, 12 A growing body of 
evidence has shown that high TMB correlates with response to PD-1/L1 inhibitors,13–18 but 
not non-ICI therapies,18 across different cancer types. Prior work has also shown that loss of 
the tumor suppressor PTEN may be linked to poor responses to PD-1 blockade in patients 
with melanoma and uterine leiomyosarcoma19, 20 and PTEN is frequently altered in TNBC.
21 However, in mTNBC, data about the relationship of high TMB and PTEN alterations with 
immunotherapy response are lacking. Therefore, the aim of this work was to evaluate the 
association of high TMB and PTEN alterations with ICI efficacy in patients with mTNBC.
Methods
Study Cohort
We included patients with mTNBC, defined as the absence of HER2 amplification and 
estrogen and progesterone receptor expression (<1%), treated with anti-PD-1/L1 therapy as 
monotherapy or in combination with chemotherapy or targeted therapy at the Dana-Farber 
Cancer Institute. Eligible patients prospectively provided written consent for research tumor 
genomic sequencing under protocol #11–104 and underwent targeted DNA sequencing 
(OncoPanel) on either an archival metastatic (47%), primary (45%), local recurrence (6%), 
or unknown (2%) tumor sample. This current project was performed after receiving approval 
by the Dana-Farber/Harvard Cancer Center Institutional Review Board (DF/HCC Protocol 
#18–082) and conducted in accordance with the ethical guidelines outlined by the Belmont 
Report.
Genomic and PD-L1 Assessment
Performed in a Clinical Laboratory Improvement Amendments-certified laboratory 
environment, OncoPanel uses targeted exome sequencing to detect copy number alterations, 
single nucleotide variants, and translocations across the full coding regions and selected 
intronic regions of a predefined subset of cancer-related genes with tumor-derived DNA.22 
In this study, the majority of patients (n=44) had testing done using OncoPanel version 2,23 
which targets the full coding regions or selected intronic regions of 335 genes (exonic 
coverage region = 0.82 megabase [Mb]). Four patients were assessed with OncoPanel 
version 1,24, 25 which targets 305 genes (exonic coverage region = 0.75 Mb), and 14 patients 
were evaluated with OncoPanel version 3,22 targeting 507 genes (exonic coverage region = 
1.3 Mb). TMB was calculated as the number of nonsynonymous somatic mutations per 
megabase of exonic sequence data covered by each panel. All nonsynonymous mutations, 
including nonsense, missense, frame-shift, splice site, and nonstop changes, were 
considered. High TMB was defined as ≥10 mutations/Mb, and PTEN alterations were 
defined as nonsynonymous mutations or 1 or 2 copy deletions, based on prior work showing 
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that partial PTEN deletions are associated with poor prognosis in breast cancer.26 All 
patients but one had OncoPanel performed on samples collected before exposure to 
immunotherapy.
PD-L1 expression was centrally evaluated (Q2 Solutions, Valencia, CA) during screening on 
patients treated with pembrolizumab (n = 37) using the PD-L1 IHC22C3 pharmDx kit 
(Agilent, Carpinteria, CA). Expression was measured by the combined positive score (CPS), 
defined as the ratio of PD-L1-positive cells (tumor cells, lymphocytes, and macrophages) to 
the total number of tumor cells. PD-L1 positivity was defined as CPS > 1.
Statistical Analysis
Responses were prospectively assessed by Response Evaluation Criteria in Solid Tumors 
(RECIST) version 1.1 during each clinical trial. PFS was defined as the date of starting 
immunotherapy to the date of progression, death, or last follow-up. OS was defined as the 
date of starting immunotherapy until the date of death or last follow-up. Patients alive and 
without progression at last follow-up were censored for PFS, and those still alive were 
censored for OS. The associations of high TMB and PTEN alterations with objective 
response rate (ORR), PFS, and OS were assessed with logistic regression for ORR and the 
Kaplan-Meier method, log-rank tests, and Cox proportional hazards regression for PFS and 
OS. Multivariate regression models adjusted for the following clinical factors: Eastern 
Cooperative Oncology Group performance status (ECOG PS) at trial enrollment (≥1 versus 
0), therapy regimen (monotherapy versus combination therapy, which showed the same 
significant associations as adjustment by individual therapy regimen, data not shown), 
number of prior systemic metastatic therapies (≥1 versus 0), and presence of visceral 
metastasis (yes versus no). Analyses were performed in RStudio Version 1.2.5001.
Results
Patient Characteristics
Between April 2014 and January 2019, 62 women with mTNBC met the inclusion criteria 
for this analysis. These women were enrolled on 6 different clinical trials with anti-PD-1/L1 
therapy: 14 (23%) patients received ICIs as monotherapy (pembrolizumab [n=7, 
NCT02447003]; atezolizumab [n=7; NCT01375842]), and 48 (77%) received ICIs in 
combination with chemotherapy (pembrolizumab plus eribulin [n=30; NCT02513472]; 
atezolizumab plus nab-paclitaxel [n=6; NCT01633970]) or targeted therapy (nivolumab plus 
cabozantinib [n=9; NCT03316586]; pembrolizumab plus niraparib [n=3; NCT02657889]). 
At baseline, the median age was 55 years (range 32–76); 68% had an ECOG PS of 0; 74% 
had visceral metastasis; and 60% had received one or more prior systemic therapies for 
metastatic disease (Table 1). The median follow-up was 13.5 months, and there were 54 
progression events and 44 deaths. Eight patients remained free of disease progression: 3 
patients continued on immune checkpoint inhibitor therapy, 3 stopped treatment per protocol 
after 2 years of therapy, and 2 stopped due to toxicity. Overall, the median PFS and OS for 
the entire cohort were 4.2 and 16.0 months, respectively.
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TMB, PTEN Alterations, and PD-L1 Status
The median TMB was 6 mutations/Mb, and 12 (18%) patients were classified as having high 
TMB. The most commonly mutated genes were TP53 (51; 82%), BRCA1 (10; 16%), and 
ATM (8; 13%; eFigure 1 in the Supplement). A total of 18 (29%) patients had PTEN 
alterations, including 10 patients with 1 copy deletions, 6 patients with nonsynonymous 
alterations, 1 patient with a 2 copy deletion, and 1 patient with a 1 copy deletion and a 
nonsynonymous alteration. Of the 18 patients with PTEN alterations, 3 also had high TMB. 
Patients with PTEN alterations had the same mean TMB (7.5 vs 7.3 mutations/Mb) and a 
higher median TMB (8.2 vs. 5.3 mutations/Mb) than patients without PTEN alterations.
PD-L1 expression was assessed on 37 tumors and was positive in 14 (38%) cases (Table 1). 
The cohort of patients with known PD-L1 status was generally representative of the overall 
cohort (eTable 1 in the Supplement), except for a slightly higher portion of patients receiving 
immunotherapy as first-line treatment for metastatic disease (54% vs. 40% in the overall 
cohort). The ORR was numerically higher in PD-L1-positive tumors (57%) versus PD-L1-
negative tumors (35%; p=0.3 by Fisher’s exact). Among tumors with high TMB and known 
PD-L1 status (n=10), 3 (30%) were PD-L1 positive, while among those without high TMB 
(n=27), 11 (41%) tumors were PD-L1 positive (p=0.7 by Fisher’s exact). The median TMB 
was also not statistically different between patients with PD-L1-positive and negative tumors 
(Wilcoxon test p=0.7; eFigure 2 in the Supplement). Likewise, among tumors with PTEN 
alterations and known PD-L1 status, 3 (27%) were PD-L1 positive, while among those 
without PTEN alterations, 11 (42%) tumors were PD-L1 positive (p=0.5 by Fisher’s exact).
High TMB and PTEN Alterations Associate with ORR, PFS, and/or OS in ICI Cohort
The ORR was numerically higher for patients with high TMB (58%) versus those with low 
TMB (30%; p=0.09 by Fisher’s exact) and significantly lower for patients with PTEN 
alterations (6%) versus those without PTEN alterations (48%; p=0.001 by Fisher’s exact). 
Univariate analyses showed that patients with high TMB had a 3.3 times higher odds of 
response than patients without high TMB (odds ratio [OR] 3.27, 95% CI 0.90–12.67, 
p=0.07), and patients with PTEN alterations had a 94% lower odds of response than patients 
without PTEN alterations (OR 0.06, 95% CI 0.003–0.36, p=0.01). In multivariate analyses, 
patients with high TMB had a 4 times higher odds of response than patients without high 
TMB (OR 4.32, 95% CI 1.05–19.89, p=0.05), and patients with PTEN alterations had a 94% 
lower odds of response than patients without PTEN alterations (OR 0.06, 95% CI 0.003–
0.34, p=0.01), independent of clinical factors. In the 37 patients with known PD-L1 status, 
high TMB was associated with a numerically higher odds of response (OR 3.17, 95% CI 
0.61–19.57, p = 0.18), and PTEN alterations were still associated with a significantly lower 
odds of response (OR 0.07, 95% CI 0.003–0.51, p = 0.02) after adjustment for clinical 
factors and PD-L1.
Patients with high TMB experienced longer median PFS (12.5 months, 95% CI 6.3-not 
reached) versus patients without high TMB (3.7 months, 95% CI 2.3–5.8, log-rank p=0.03; 
Figure 1A), while patients with PTEN alterations experienced shorter median PFS (2.3 
months, 95% CI 2.0–4.2) versus patients without PTEN alterations (6.1 months, 95% CI 
3.9–9.1, log-rank p=0.01; Figure 1B). Similarly, patients with high TMB also experienced 
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longer survival (median OS 29.2 months, 95% CI 20.5-not reached) versus patients without 
high TMB (median OS 14.2 months, 95% CI 11.6–24.5, log-rank p=0.06; Figure 1C), while 
patients with PTEN alterations experienced shorter survival (median OS 9.7 months, 95% CI 
5.0–34.6) versus patients without PTEN alterations (median OS 20.5 months, 95% CI 13.8–
33.2, log-rank p=0.01; Figure 1D).
In univariate analyses, patients with high TMB had significantly longer PFS (hazard ratio 
[HR] 0.46, 95% CI 0.22–0.95, p=0.04) and numerically higher OS (HR 0.48, 95% CI 0.22–
1.05, p=0.07) versus those without high TMB, while patients with PTEN alterations had 
significantly shorter PFS (HR 2.04, 95% CI 1.15–3.63, p=0.01) and significantly worse OS 
(HR 2.19, 95% CI 1.16–4.13, p=0.02) versus patients without PTEN alterations (Table 2). 
Multivariate analyses confirmed that patients with high TMB experienced significantly 
longer PFS (HR 0.42, 95% CI 0.19–0.93, p=0.03) and numerically higher OS (HR 0.54, 
95% CI 0.23–1.26, p=0.15), while patients with PTEN alterations had significantly shorter 
PFS (HR 2.71, 95% CI 1.44–5.10, p=0.002) and OS (HR 3.26, 95% CI 1.59–6.68, p=0.001), 
independent of clinical factors (Figure 2). In two final multivariate models, the first 
including both high TMB and PTEN alterations in addition to clinical factors and the second 
adding PD-L1 status to the first, both high TMB and PTEN alterations remained 
significantly associated with longer and shorter PFS, respectively, and PTEN alterations 
remained significantly associated with shorter OS (Table 2). Alterations in other 
immunotherapy-related pathways did not show statistically significant associations with 
response (eResults and eTable 2 in the Supplement).
To explore whether high TMB and PTEN alterations are predictive or prognostic, we 
examined the association of high TMB and PTEN alterations with PFS and OS in previously 
published mTNBC cohorts treated with chemotherapy (n = 90) and non-ICI regimens (n = 
169, eMethods in the Supplement).27 We analyzed PFS and OS in 90 patients with mTNBC, 
who underwent pre-treatment targeted DNA sequencing (MSK-IMPACT; 57% with 410-
gene version 2 covering 1.016478 Mb of exon) on either a metastatic (62%) or primary 
(34%) tumor sample and were treated with single-agent chemotherapy (71%) or 
combination chemotherapy (29%) that was not labeled as neoadjuvant or adjuvant treatment.
27 We also analyzed OS in 169 patients with mTNBC treated with regimens that did not 
include immune checkpoint inhibitors (ICIs).27 In these cohorts, neither high TMB nor 
PTEN alterations were associated with PFS and/or OS in univariate or multivariate analyses 
adjusted for prior lines of metastatic therapy (≥1 versus 0) and chemotherapy regimen 
(monotherapy vs. combination; eTable 3 and eFigures 3–5 in the Supplement).
Discussion
Prior work has shown that high TMB is associated with higher response rates and prolonged 
PFS following anti-PD-1/L1 therapy across different tumor types,7, 10, 13–15, 28–32 and that 
PTEN loss is linked to inferior responses to PD-1 blockade and resistance to T cell-mediated 
immunotherapy.19, 20 However, the relationship of high TMB and PTEN alterations with 
immunotherapy response in mTNBC has not previously been well characterized. In this 
mTNBC cohort with comprehensive clinical and genomic annotations, we observed a 
significant positive association of high TMB with longer PFS and a significant negative 
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association of PTEN alterations with lower ORR and shorter PFS and OS among patients 
with mTNBC treated with anti-PD-1/L1 therapies. Importantly, these associations remained 
significant after adjustment for PD-L1 status and clinical confounders, including 
monotherapy versus combination regimen and first versus higher treatment line, indicating 
that these factors are unlikely explanations for the observed associations.
The identification of biomarkers that predict clinical benefit to ICI-based therapies is needed 
to better select patients who are more likely to benefit from therapy and spare patients less 
likely to benefit from immunotherapy toxicity. To date, there are only 2 validated and 
clinically available biomarkers that predict benefit to ICI: mismatch repair deficiency 
(dMMR)33 and PD-L1 expression.34 Yet dMMR is rare in breast cancer, occurring in < 2% 
of tumors, more commonly in early stage disease.33 As for PD-L1, the phase III 
IMpassion130 study showed that the combination of atezolizumab plus nab-paclitaxel was 
superior to nab-paclitaxel alone only for patients with treatment-naïve mTNBC tumors with 
≥ 1% PD-L1-positive immune cells by the SP142 antibody.6 This led to the recent FDA 
approval for this regimen in PD-L1-positive patients. However, a minority of patients with 
TNBC have PD-L1-positive tumors by the approved companion diagnostic PD-L1 SP142 
assay, ranging from 40% in IMpassion130,6 which included primary and metastatic tumors, 
to 25% of mTNBC tumors at our institution. Concerns remain regarding the utility of PD-L1 
expression as a reliable biomarker, including its dynamic nature with varying expression 
over time, the discordance among different PD-L1 assays, and the fact that some PD-L1-
negative patients respond to ICIs.35
Thus, there is an unmet need to define better biomarkers to predict benefit and resistance to 
immunotherapy in mTNBC, and high TMB and PTEN alterations are possible candidates. 
Using publicly available genomic data from 3969 patients with breast cancer from 6 
different cohorts, our group previously showed that 5% of breast cancers have high TMB 
and that metastatic tumors have a greater prevalence of high TMB than primary tumors 
(8.4% vs 2.9%).36 In addition, that study showed that high TMB tumors had greater immune 
cytolytic activity,7 as measured by the RNA expression of the CD8-positive T cell effectors 
GZMA and PRF1, suggesting that these patients are more likely to respond to ICI therapies. 
Likewise, PTEN loss correlated with decreased T cell infiltration, reduced T cell expansion, 
and worse response to PD-1 inhibitors in other tumors.19, 20 Thus, there is reason to 
hypothesize that TMB and PTEN alterations may be correlates of response to ICIs.
This study showed that high TMB was significantly associated with longer PFS independent 
of clinical factors and PD-L1 status. These results are supported by the TAPUR study, a 
prospective clinical trial of single-agent pembrolizumab in heavily pre-treated metastatic 
breast cancer patients with TMB ≥ 9 mutations/Mb, which reported an overall response rate 
of 21% and a durable clinical benefit rate of 37%.37 In addition, other studies have shown 
that TMB and PD-L1 expression are independent predictive markers of response to ICI 
therapies and have low correlation across multiple cancers.16, 17 In fact, higher TMB has 
been associated with worse response to non-ICI treatments in metastatic breast cancer.38 
Samstein et al. similarly showed that there was no association between TMB and OS in a 
cohort of 860 patients with breast cancer treated with non-ICI therapies,18 which we 
similarly concluded examining only patients with TNBC from the same institution. The 
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Samstein et al. study also had a small cohort of patients with metastatic breast tumors treated 
with ICIs (n = 45), including 25 patients with ER-negative tumors, which did not 
demonstrate an association between high TMB and OS. However, only 4 of the 45 patients 
included in this cohort had tumors with TMB ≥10 mutations/Mb, 20 patients (45%) received 
single-agent anti-CTLA-4 therapy, and the clinical outcome data were not directly accessed 
from structured clinical trials. In contrast, all patients in the present study received anti-
PD-1/L1-based regimens on a clinical trial.
This study also demonstrated that PTEN alterations were significantly associated with lower 
ORR and shorter PFS and OS independent of clinical factors and PD-L1 status. Prior 
analyses have demonstrated that partial PTEN deletions associate with worse OS in breast 
cancer.26 These findings highlight the importance of determining whether PTEN alterations 
are predictive or prognostic and prompted our analyses of PTEN alterations in patients with 
mTNBC treated with chemotherapy and non-ICI therapies, which, although underpowered, 
suggested that PTEN alterations are not prognostic. Regardless, the present findings about 
PTEN alterations underlying ICI resistance are directly applicable to the current clinical 
development of immunotherapy combinations in mTNBC. Consistent with the finding that 
PI3K/AKT pathway inhibition reversed resistance to T-cell mediated immunotherapy in 
murine models19, a phase 1b study of the AKT-inhibitor ipatasertib and (nab)-paclitaxel 
combined with atezolizumab in 26 patients with mTNBC demonstrated an impressive ORR 
of 73%, which represents an improvement over doublet regimens of taxane chemotherapy 
combined with atezolizumab or ipatasertib across biomarker subgroups.39 Several larger 
trials are currently being developed to further investigate the combination of AKT inhibitors, 
PD-1/L1 inhibitors, and chemotherapy in patients with mTNBC. Whether future trials 
confirm that PTEN-altered mTNBC harbors ICI resistance that may be reversed by 
PI3K/AKT/mTOR inhibitors remains to be determined.
Limitations
This analysis of prospectively treated patients has several limitations, including the small 
sample size, the heterogeneity of prior and current therapy regimens including monotherapy 
and combination immunotherapy regimens, and the lack of functional validation that the 
observed PTEN alterations, which included single copy deletions, led to decreased PTEN 
expression in tumors. In addition, the prevalence of high TMB in this study was higher than 
previously reported. Possible explanations include that OncoPanel only evaluates tumor 
without concurrent germline DNA and that high TMB tumors were assessed with OncoPanel 
versions covering < 1 Mb of exome, which can overestimate TMB versus whole exome 
sequencing.32, 40 Moreover, the ideal cutoff for defining high TMB in mTNBC is unknown. 
We used the same cutoff as reported in the large pan-cancer analysis by Campbell et al.41 
Overall, our study alone does not prove that TMB and PTEN alterations are predictive 
biomarkers. Instead, additional validation studies, including analyses of TMB and PTEN 
alterations in larger cohorts of immunotherapy and non-immunotherapy treated patients, are 
required to establish these correlates as predictive biomarkers of response to ICIs in 
mTNBC.
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As the first genomic analysis of anti-PD-1/L1 response in a mTNBC cohort with in-depth 
clinical annotations, this study found that patients with versus without high TMB were more 
likely to experience longer PFS and that patients with versus without PTEN alterations were 
more likely to progress and experience shorter PFS and OS, even after adjustment for 
clinical heterogeneity and PD-L1 status. Prospective studies are required to validate the 
associations of high TMB and PTEN alterations with ICI response in mTNBC and to 
determine whether these findings are generalizable to early stage TNBC. To elucidate the 
role of high TMB, we designed a currently enrolling multicenter phase II trial of nivolumab 
plus ipilimumab in metastatic HER2-negative breast cancers with high TMB (NIMBUS, 
NCT03789110). Similarly, the role of PTEN alterations may be clarified in ongoing clinical 
trials investigating whether AKT inhibitors reverse resistance to PD-1 blockade.
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Figure 1. Kaplan-Meier Curves for Progression-Free and Overall Survival by Biomarker Status 
in Anti-PD-1/L1-Treated Cohort.
(A) Progression-free survival and (C) overall survival by tumor mutational burden status 
(<10 vs ≥10 mutations/megabase); (B) progression-free survival and (D) overall survival by 
PTEN alteration (absent vs present). Abbreviations: TMB: tumor mutational burden; WT: 
wild type.
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Figure 2. Adjusted Hazard Ratios (HR) for Progression-Free Survival (PFS) and Overall 
Survival (OS) by Biomarker Status in Anti-PD-1/L1-Treated Cohort.
PFS and OS HRs by TMB ≥10 vs. <10 mutations/megabase and PTEN alterations (present 
vs. absent), adjusted for ECOG PS (≥ 1 vs. 0), previous lines of therapy (≥ 1 vs. 0), regimen 
(monotherapy vs. combination therapy), and visceral metastases (present vs. absent). 
Abbreviations: ECOG-PS: Eastern Cooperative Oncology Group performance status; CI: 
confidence interval; HR: hazard ratio; TMB: tumor mutational burden.
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Table 1.
Baseline characteristics
Characteristic Total (n = 62) Not High TMB (n = 50) High TMB (n = 12) PTEN WT (n = 44) PTEN Altered (n = 18)
Age, yrs, median (range) 55 (32–76) 55 (32–71) 58 (42–76) 56 (32–76) 52 (37–76)
Female, N (%) 62 (100) 50 (100) 12 (100) 44 (100) 18 (100)
ECOG-PS, N (%)
 0 42 (68) 32 (64) 10 (83) 31 (70) 11 (61)
 1 20 (32) 18 (36) 2 (17) 13 (30) 7 (39)
Visceral metastases 46 (74) 35 (70) 11 (92) 31 (70) 15 (83)
Prior therapies for metastatic disease
 Median (range) 1 (0–6) 1 (0–6) 1 (0–2) 1 (0–6) 1 (0–6)
 0, N (%) 25 (40) 20 (40) 5 (42) 17 (39) 8 (44)
 1, N (%) 19 (31) 15 (30) 4 (33) 14 (32) 5 (28)
 2, N (%) 13 (21) 10 (20) 3 (25) 10 (23) 3 (17)
 ≥3, N (%) 5 (8) 5 (10) 0 (0) 3 (7) 2 (11)
Previous therapy, N (%)
 Neo(adjuvant) therapy 57 (92) 64 (92) 11 (92) 41 (93) 16 (89)
 Taxanes 56 (90) 44 (88) 12 (100) 39 (89) 17 (94)
 Anthracycline 51 (82) 40 (80) 11 (92) 36 (82) 15 (83)
Regimen, N (%)
 Monotherapy 14 (23) 10 (20) 4 (33) 12 (27) 2 (11)




 Positive 14 (38) 11 (41) 3 (30) 11 (42) 3 (27)
 Negative 23 (62) 16 (59) 7 (70) 15 (58) 8 (73)
ORR (%) 35 30 58 48 6
a
The PD-L1 analysis included 37 patients.
Abbreviations: ECOG-PS: Eastern Cooperative Oncology Group performance status; ORR: objective response rate; TMB: tumor mutational 
burden; WT: wild type; yrs: years
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Table 2.
Univariate and multivariate analysis of factors associated with progression-free and overall survival following 
immune checkpoint-inhibitor-based therapies
Progression-Free Survival Overall Survival
HR 95% CI p-value HR 95% CI p-value
Univariate Models (n = 62)
High TMB 0.46 0.22–0.95 0.04 0.48 0.22–1.05 0.07
PTEN alteration 2.04 1.15–3.63 0.01 2.19 1.16–4.13 0.02
ECOG PS 1.72 0.58–3.05 0.06 3.24 1.74–6.04 0.0002
Previous lines of therapy 1.57 0.91–2.71 0.11 1.39 0.75–2.56 0.30
Regimen 1.31 0.69–2.49 0.41 1.14 0.57–2.26 0.72
Visceral metastases 1.10 0.59–2.06 0.77 1.11 0.56–2.20 0.77
High TMB Multivariate Model (n = 62)
High TMB 0.42 0.19–0.93 0.03 0.54 0.23–1.26 0.15
ECOG PS 1.64 0.89–3.00 0.11 2.93 1.53–5.63 0.001
Previous lines of therapy 1.57 0.89–2.76 0.12 1.29 0.68–2.45 0.43
Regimen 1.83 0.90–3.73 0.10 1.54 0.71–3.35 0.27
Visceral metastases 1.50 0.79–2.86 0.22 1.35 0.65–2.82 0.42
PTEN Alteration Multivariate Model (n = 62)
PTEN alteration 2.71 1.44–5.10 0.002 3.26 1.59–6.68 0.001
ECOG PS 1.98 1.08–3.62 0.03 3.84 1.99–7.39 0.00006
Previous lines of therapy 1.83 1.02–3.29 0.04 1.57 0.81–3.06 0.18
Regimen 1.84 0.90–3.74 0.09 1.69 0.78–3.62 0.18
Visceral metastases 1.21 0.64–2.30 0.56 1.05 0.52–2.14 0.88
High TMB and PTEN Alteration Multivariate Model (n = 62)
High TMB 0.37 0.17–0.80 0.01 0.48 0.20–1.14 0.10
PTEN alteration 3.07 1.62–5.81 0.0006 3.44 1.67–7.07 0.0008
ECOG PS 1.67 0.91–3.05 0.10 3.34 1.72–6.49 0.0004
Previous lines of therapy 1.79 1.00–3.21 0.05 1.48 0.76–2.87 0.25
Regimen 2.38 1.15–4.96 0.02 2.05 0.92–4.55 0.08
Visceral metastases 1.45 0.75–2.78 0.27 1.28 0.61–2.67 0.52
High TMB, PTEN Alteration, and PD-L1 Multivariate Model (n = 37)
High TMB 0.37 0.15–0.91 0.03 0.42 0.16–1.11 0.08
PTEN alteration 2.82 1.16–6.85 0.02 2.93 1.14–7.53 0.03
PD-L1 0.78 0.31–1.93 0.59 1.28 0.48–3.43 0.63
ECOG PS 1.16 0.47–2.87 0.74 2.27 0.90–5.73 0.08
Previous lines of therapy 1.41 0.62–3.18 0.41 1.39 0.59–3.30 0.45
Regimen 1.18 0.41–3.42 0.76 1.70 0.58–4.97 0.33
Visceral metastases 0.71 0.27–1.88 0.50 1.00 0.39–2.59 0.99
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High TMB: ≥ 10 mutations/megabase vs. < 10 mutations/megabase; PTEN alteration (nonsynonymous mutation or 1 or 2 copy deletion): present 
vs. absent; PD-L1: positive vs. negative; ECOG PS: ≥ 1 vs. 0; Previous lines of therapy: ≥ 1 vs. 0; Regimen: monotherapy vs. combination therapy; 
Visceral metastases: present vs. absent.
Abbreviations: CI: confidence interval; ECOG-PS: Eastern Cooperative Oncology Group performance status; HR: hazard ratio; TMB: tumor 
mutational burden.
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